ConductScience.org, home

Paper36764323

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.

Sallman DA and 18 others. Lancet Haematol, 2023. Cited by 102 papers, by iCite.

Cite this record

ConductScience Library. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Papers, record 36764323. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36764323

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
PubMed
Journal
Lancet Haematol
PubMed
Year
2023
PubMed
Publication types
Clinical Trial, Phase I, Journal Article
PubMed
Citations, by iCite
102
iCite
Relative citation ratio, by iCite
8.1
iCite
Revised in PubMed
2023-03-17
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sallman DADavid A
2Kerre TTessa
3Havelange VViolaine
4Poiré XXavier
5Lewalle PPhilippe
6Wang ESEunice S
7Brayer JBJason B
8Davila MLMarco L
9Moors IIne
10Machiels JPJean-Pascal
11Awada AAhmad
12Alcantar-Orozco EMErik M
13Borissova RRossitza
14Braun NNathalie
15Dheur MSMarie-Sophie
16Gilham DEDavid E
17Lonez CCaroline
18Lehmann FFFrédéric F
19Flament AAnne

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple MyelomaMajor topic
Leukemia, Myeloid, AcuteMajor topic
Myelodysplastic SyndromesMajor topic
Humans
NK Cell Lectin-Like Receptor Subfamily K
Immunotherapy, Adoptive
Cytokine Release Syndrome

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03018405A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer IndicationsDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in36764324Taking a step forward in CAR T-cell therapy for acute myeloid leukaemia and myelodysplastic syndrome.https://conductscience.org/library/papers/36764324

Source PubMed

Download CSV of comments and corrections

Cited by80

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 102 citations.

PMIDTitleJournalYearIn PapersSource
42801642A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42801642PubMed
42681647A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm.J Hematol Oncol2026https://conductscience.org/library/papers/42681647PubMed
42645167Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies.Cells2026https://conductscience.org/library/papers/42645167PubMed
42575882CAR T cell therapy beyond cancer: current status, challenges and future prospects.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42575882PubMed
42528842Immunological barriers and engineering strategies for CAR-T cell therapy in acute myeloid leukemia.Front Immunol2026https://conductscience.org/library/papers/42528842PubMed
42519395Pediatric AML CAR T cell therapy.Mol Ther Oncol2026https://conductscience.org/library/papers/42519395PubMed
42460416Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review.Mol Ther Adv2026https://conductscience.org/library/papers/42460416PubMed
42399624CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.Leukemia2026https://conductscience.org/library/papers/42399624PubMed
42380095Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42380095PubMed
42241897Successful autologous T cell apheresis in pediatric patients with hematologic malignancies, solid tumors, and brain tumors.Cytotherapy2026https://conductscience.org/library/papers/42241897PubMed
42180870Targeting the MICA/B-NKG2D axis in cancer: from molecular structure to immunotherapeutic strategies-a narrative review.Transl Cancer Res2026https://conductscience.org/library/papers/42180870PubMed
42034501Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure.Blood Rev2026https://conductscience.org/library/papers/42034501PubMed
42033215Advances in natural killer cell immunotherapy for hematologic malignancies.Cancer Biol Ther2026https://conductscience.org/library/papers/42033215PubMed
41802812Targeting endosomal trafficking-mediated antigen escape to resensitize myeloma to CAR-T therapy.J Immunother Cancer2026https://conductscience.org/library/papers/41802812PubMed
41800605Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation.Ann Med2026https://conductscience.org/library/papers/41800605PubMed
41799370Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy.Immunooncol Technol2026https://conductscience.org/library/papers/41799370PubMed
41622937Synergistic immune interactions between T cells and natural killer cells in allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: current status and future directions.Ann Med2026https://conductscience.org/library/papers/41622937PubMed
41578095The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/41578095PubMed
41521321Molecularly targeted therapy and immunotherapy in leukemias.J Hematol Oncol2026https://conductscience.org/library/papers/41521321PubMed
41490616[Research progress of the ULBP-NKG2D axis in autoimmune diseases].Zhejiang Da Xue Xue Bao Yi Xue Ban2026https://conductscience.org/library/papers/41490616PubMed

See all 80 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
KLRK122914PubTator's text mininghttps://conductscience.org/library/genes/22914NCBI Gene
NR1I39970PubTator's text mininghttps://conductscience.org/library/genes/9970NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36764323

GET https://conductscience.org/api/papers/v1/36764323/cited_by?page=2